Skip to main content
Equibles
MIST logo

MIST · Milestone Pharmaceuticals Inc.

Track MIST — free Ask ALVIS about MIST
$1.15 -0.03 (-2.14%) At close · Aug 5
Market Cap
$142.55M
Shares
124.50M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.15 Open$1.20 Day$1.13–1.20 52W$1.00–3.06 Avg vol 30d1.3M Short int14.6M · 11.7% float · 13.6d Short vol48% Last earningsMay 13, 2026 DataJan 2020–Aug 2026 Filing10-Q · May 13

Up next

Next earnings call
Feb 6, 2027 Est · unconfirmed · in 26 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 13, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
      Market backdrop VIX 15.8 · calm Equity put/call 0.46
      Technical
      price trend
      Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −34%
      below
      Price vs 50-day avg −9%
      below
      RSI (14) 44
      neutral
      MACD trend Positive
      52-week position 7%
      near low
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Weak
      1-month return −6%
      trailing
      6-month return −37%
      trailing
      YTD return −43%
      this year
      Relative strength −48%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $1 › 200d $2 — 200d above 50d
      Institutional flow Accumulating
      20 of 86 funds reported for Jun 30 · net +1.8M sh shares
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      11.71% of float · ▲ +15.8% MoM · 13.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      86 holders — near 3-yr high, broad support
      Squeeze score 70
      elevated · 0–100
      Fundamentals
      Weak
      EPS growth −12%
      Y/Y
      Free cash flow $-49.3M
      Balance sheet $15.9M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 71%
      annualized · 1-yr
      Max drawdown −66%
      past year
      ATR 6.5%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Sell
      3 · 3 · 1
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −34% Bearish
      Price vs 50-day avg
      −9% Bearish
      RSI (14)
      44 Neutral
      MACD trend
      Positive Bullish
      52-week position
      7% Bearish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 2 of 6
      Trend (MA cross) No cross
      50d $1 › 200d $2 — 200d above 50d
      Institutional flow Accumulating
      20 of 86 funds reported for Jun 30 · net +1.8M sh shares
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      11.71% of float · ▲ +15.8% MoM · 13.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      86 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      52-wk low $1 Now $1 · 7% 52-wk high $3
      vs 200-day avg -34% vs 50-day avg -9%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      commercially insured lives in the U.S. now have coverage for CARDAMYST 25% Q1 FY2026 —
      patients with PSVT 560 through April —
      scripts for CARDAMYST have been filled 600 through April —
      unique prescribers have started patients on CARDAMYST 400 through April —
      Pro forma cash $200M FY2025 —
      Royalty payment received from RTW $75M January 12, 2026 —
      Sales force size 60 FY2025 —

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      MIST
      Milestone Pharmaceuticals Inc.
      this stock
      		$142.55M -43.3% — — 11.7%
      ONC
      BeOne Medicines Ltd.
      		 $484.13B +7.8% +22179.2% 744.4 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $122.89B +6.9% +46.2% 28.2 2.0%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $79.13B -0.2% +20.8% 19.0 3.4%
      ARGX
      Argenx SE
      		 $54.30B +3.2% — — 2.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      84
      % held
      26.2%
      Reported
      20 of 86
      Top holder
      RTW INVESTMENTS, LP
      Held Float
      View
      Held by Funds
      Fund positions
      5
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      14.6M
      Days to cover
      13.6d
      Change
      +2.0M sh
      View
      Short Volume
      Short vol %
      48%
      As of
      Aug 5, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      83.6K
      Value
      $109.5K
      As of
      Jul 10, 2026
      View
      Off-Exchange
      Off-exchange %
      63.8%
      Week of
      Jun 29, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Net income (FY)
      $-63.1M
      EPS diluted
      $-0.75
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jun 15, 2026
      This year
      10
      View
      Proposed Sales
      Value
      $80.3K
      Shares
      36.5K
      Filed
      Apr 16, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      May 13, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      MIST +10.1% -6.2% -37.1% +3.2% -43.3%
      SPY +5.5% +3.3% +11.3% +3.1% +12.9%
      vs SPY +4.6% -9.4% -48.3% +0.1% -56.2%
      Key facts CIK 1408443 CUSIP 59935V107 13F (30d) 19 filings 19 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)